Nuvalent has reported phase 1/2 lung cancer data, teeing the biotech up to talk to the FDA about an approval filing that could establish its neladalkib as a challenger to Pfizer’s Lorbrena.
In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the ...
Lung cancer is a disease in which abnormal cells grow uncontrollably in the tissues of the lungs, forming tumors that can ...
Traditionally, lung cancer is associated with older patients, specifically men who smoked. But doctors say that's beginning ...
Investor's Business Daily on MSN
Nuvalent Unveils A New Promise For Hard-To-Treat Lung Cancer
Nuvalent said Monday almost a third of patients with a hard-to-treat form of lung cancer responded to its experimental ...
ERS 2025 covered lung cancer treatment advances like robot-assisted bronchoscopy with integrated cone-beam CT (RAB-CBCT) and ...
The 5-year lung cancer survival rate has increased more than 25% over the past decade, highlighting the impact of increased ...
Lung cancer remains the leading cause of cancer death in the U.S., responsible for about 1 in 4, but major advances in ...
Scientists used CRISPR to disable the NRF2 gene, restoring chemotherapy sensitivity in lung cancer cells and slowing tumor ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback